Clinical Scorecard: FDA approves first at-home therapy for thyroid eye disease
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: FDA approves first at-home therapy for thyroid eye disease |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | Adults with thyroid eye disease (TED). The SatraGO-1 and SatraGO-2 trials enrolled patients with active, moderate-to-severe, and chronic TED. |
| Care Setting | Care setting described in the source article. |
Key Highlights
- The FDA approved satralizumab-mwge (Enspryng) for adults with TED; it is the first and only approved at-home subcutaneous treatment for the condition, according to Genentech.
- In SatraGO-2, 52.9% of satralizumab-treated patients and 23.4% of placebo-treated patients achieved a proptosis reduction of at least 2 mm at week 24.
- SatraGO-1 did not meet its prespecified primary end point; proptosis response rates were 49.0% with satralizumab and 31.2% with placebo.
- In SatraGO-2, diplopia improved in 60.7% of satralizumab-treated patients versus 25.8% of placebo-treated patients.
- The trials identified no new safety signals; no serious infections occurred in satralizumab groups during the 24-week assessment.
Guideline-Based Recommendations
Diagnosis
Management
- According to the prescribing information, administer satralizumab-mwge subcutaneously at weeks 0, 2, and 4, followed by maintenance injections every 4 weeks.
- Patients may self-administer or have a caregiver administer injections after training.
- Delay treatment during active infection.
Monitoring & Follow-up
- Before treatment, screen for hepatitis B and tuberculosis and assess liver transaminases.
- During treatment, monitor for infections, elevated liver enzymes, and reduced neutrophil counts.
Risks
- Contraindications include hypersensitivity, active hepatitis B infection, and active or untreated latent tuberculosis.
- The trials reported low rates of serious adverse events and treatment discontinuation; no serious infections occurred in satralizumab groups during the 24-week assessment.
Patient & Prescribing Data
Adults with TED. SatraGO-1 and SatraGO-2 enrolled 258 adults across 19 countries and evaluated active, moderate-to-severe, and chronic TED.
Subcutaneous loading injections are given at weeks 0, 2, and 4, followed by injections every 4 weeks. Administration may be by the patient or a trained caregiver.
Clinical Best Practices
- Screen for hepatitis B and tuberculosis and assess liver transaminases before starting treatment.
- Monitor for infection, elevated liver enzymes, and reduced neutrophil counts during treatment.
- Do not use in patients with hypersensitivity, active hepatitis B infection, or active or untreated latent tuberculosis; delay treatment during active infection.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
